Business Context and Reporting Period
Company: BIOHARVEST SCIENCES INC.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: November 2025
Date of Filing: November 7, 2025
Principal Executive Offices: Vancouver, British Columbia, Canada
This filing serves as a Material Change Report (MCR) submitted pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. The registrant files annual reports under Form 40-F.
Key Financial Metrics
The provided filing text contains only cover page metadata and exhibit listings. It does not include specific financial statements or data tables. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Note: The filing text does not provide a clear value for any financial metric.
Material Changes
The filing discloses a material change event occurring on or around November 6, 2025, evidenced by the attached exhibits:
- Underwriting Agreement: Schedule A to the MCR references an Underwriting Agreement dated November 6, 2025.
- Public Announcements: Two news releases are attached (Schedule B dated November 6, 2025, and Schedule C dated November 7, 2025).
- Legal Opinion: Schedule D includes an opinion letter (5.1 Opinion).
The specific nature of the transaction (e.g., equity offering, debt issuance, or asset acquisition) is not detailed in the cover text, though the presence of an underwriting agreement strongly suggests a capital raise or financing event.
Guidance, Outlook, and Risks
The cover page of this Form 6-K does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies. These details are likely contained within the attached exhibits (specifically the News Releases and the Material Change Report itself), which are not included in the provided input text.
Investor Verification Checklist
- Review Exhibit 99.1 (Material Change Report) to understand the specific terms and purpose of the material change.
- Examine Exhibit 99.2 (Underwriting Agreement) to determine the size, price, and structure of the financing transaction.
- Read Exhibits 99.3 and 99.4 (News Releases) for management's official commentary on the transaction and its strategic impact.
- Verify the use of proceeds and any dilution effects resulting from the underwriting agreement.